Contribution of positron emission tomography/magnetic resonance imaging in musculoskeletal malignancies.
García Cañamaque L, Field CA, Furtado FS, Plaza DE Las Heras I, Husseini JS, Balza R, Jarraya M, Catalano OA, Mitjavila Casanovas M.
Q J Nucl Med Mol Imaging. 2022 Mar;66(1):3-14. doi: 10.23736/S1824-4785.21.03432-4. Epub 2021 Dec 9.
PMID:34881853
Positron Emission Tomography Molecular Imaging of the Major Neurodegenerative Disorders: Overview and Pictorial Essay, from a Nuclear Medicine Center's Perspective.
Calabria F, Leporace M, Cimini A, Ricci M, Travascio L, Bagnato A.
J Integr Neurosci. 2023 Dec 13;22(6):172. doi: 10.31083/j.jin2206172.
PMID:38176937
Positron emission tomography: state of the art.
Cai W.
Mol Pharm. 2014 Nov 3;11(11):3773-6. doi: 10.1021/mp5005383.
PMID:25364861
Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.
Willekens SM, Van Weehaeghe D, Van Damme P, Van Laere K.
Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):533-547. doi: 10.1007/s00259-016-3587-y. Epub 2016 Dec 8.
PMID:27933416
Positron Emission Tomography in Autism Spectrum Disorder: Current Status and Future Perspectives.